Summary
64 / 100 · Bulios Score
What speaks for it
- Revenue grew by 56% a year over the last 3 years.
- It holds more cash than debt: $5.10B against $1.14B.
- Analysts expect revenue to grow by 27% this fiscal year.
- Out of every 100 USD of revenue, 11 USD is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 60.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 77% a year over 5 years. Over the last 3 years it grew by 56% a year. For the next fiscal year analysts expect revenue to grow by 27%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 11 USD
- Research and development 37 USD
- Sales and administration 36 USD
- Taxes and other 4.4 USD
- Net profit 11 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 14
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $401.56 is 8.5% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 99%
- Collaboration 0.9%
By region
- UNITED STATES 56%
- CHINA 32%
- Europe 12%
Product brings in 99% of revenue.
Segments in detail